We research and develop proprietary chemically-derived allogeneic cell therapy for degenerative diseases like Parkinson’s Disease, Retinal Degenerative Diseases, Ischemic Stroke, etc. 

Our leading pipeline NouvNeu001 (Parkinson’s Disease) is scheduled to initiate Phase I clinical trial in 2023 H2.

We are a passionate team committed to developing first-in-class therapies for patients suffering from major incurable diseases. Making fast-acting and disease-reversing therapies accessible to patients in the greatest extent possible is our priority.

iRegene Therapeutics

Org chart

Teams

Offices